Expansion of the peptide therapeutics and CMC businesses through the acquisition of JITSUBO as a subsidiary
First written in FY2021-Q1. 3 of 6 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In the pharmaceutical development ecosystem segment, orders for mid-molecule active pharmaceutical ingredient process development projects using the Molecular Hiving method expanded, but sales and profit remained weak because orders in the CMC field were limited.」
Projects for mid-molecule active pharmaceutical ingredient process development using JITSUBO’s Molecular Hiving method expanded, but orders in the CMC field were limited, leaving sales and profit for the segment as a whole weak. - FY2025-H1AdvancedAnnual report
「In the peptide and nucleic acid fields, orders for mid-molecule active pharmaceutical ingredient process development projects from global pharmaceutical majors and others overseas progressed steadily.」
In the mid-molecule pharmaceuticals field, including JITSUBO, orders for mid-molecule active pharmaceutical ingredient process development projects from global pharmaceutical majors and others overseas progressed steadily. - FY2024-Q1AdvancedAnnual report
「At JITSUBO, we focused on securing process-development projects for medium-molecule active pharmaceutical ingredients from pharmaceutical manufacturers with a significant presence in the peptide and nucleic-acid fields, including global megapharma companies overseas, increasing orders and advancing the establishment of a structure for selling Tag, a key peptide raw material.」
Following the acquisition of JITSUBO, orders for mid-molecule active pharmaceutical ingredient process development projects increased in the peptide and nucleic acid fields, and preparations progressed for a Tag sales structure. - FY2023-Q3RestatedAnnual report
「In addition, ＪＩＴＳＵＢＯ株式会社 focused its sales activities on providing development support services for mid-molecule pharmaceuticals to drug manufacturers with a strong presence in the peptide and nucleic acid fields, including global pharmaceutical majors overseas.」
Following the acquisition of JITSUBO, sales activities in the peptide and nucleic acid fields and support for mid-molecule pharmaceutical development have continued to progress. - FY2021-Q2AchievedAnnual report
「Based on this resolution, スペラファーマ acquired all of JITSUBO’s shares on 30 April 2021.」
スペラファーマ completed its acquisition of all JITSUBO shares on 30 April 2021. It entered the stage of expanding its value chain from small-molecule to mid-molecule pharmaceuticals by incorporating JITSUBO’s peptide synthesis technology. - FY2021-Q1First statedAnnual report
「The Company and its consolidated subsidiary スペラファーマ株式会社 (hereinafter, “スペラファーマ”) resolved at their respective board meetings held on 7 April 2021 that スペラファーマ would acquire the shares of JITSUBO株式会社 (hereinafter, “JITSUBO”) and make it a subsidiary of スペラファーマ, thereby making it the Company’s sub-subsidiary.」
The Company resolved to have スペラファーマ acquire JITSUBO’s shares and make JITSUBO a subsidiary in April 2021. It aims to expand its value chain from small-molecule to mid-molecule pharmaceuticals by incorporating JITSUBO’s Molecular Hiving™-based process development, technology transfer, contract manufacturing and licensing of peptide active pharmaceutical ingredients.